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Modulation of c-fins proto-oncogene in an ovarian
carcinoma cell line by a hammerhead ribozyme
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Summary Co-expression of macrophage colony-stimulating factor (M-CSF) and its receptor (c-fms) is often found in ovarian epithelial
carcinoma, suggesting the existence of autocrine regulation of cell growth by M-CSF. To block this autocrine loop, we have developed
hammerhead ribozymes against c-fms mRNA. As target sites of the ribozyme, we chose the GUC sequence in codon 18 and codon 27 of c-
fms mRNA. Two kinds of ribozymes were able to cleave an artificial c-fms RNA substrate in a cell-free system, although the ribozyme against
codon 18 was much more efficient than that against codon 27. We next constructed an expression vectorcarrying a ribozyme sequence that
targeted the GUC sequence in codon 18 of c-fms mRNA. It was introduced into TYK-nu cells that expressed M-CSF and its receptor. Its
transfectant showed a reduced growth potential. The expression levels of c-fms protein and mRNA in the transfectant were clearly decreased
with the expression of ribozyme RNA compared with that of an untransfected control or a transfectant with the vector without the ribozyme
sequence. These results suggest that the ribozyme against GUC in codon 18 of c-fms mRNA is a promising tool for blocking the autocrine
loop of M-CSF in ovarian epithelial carcinoma.
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Ovarian epithelial carcinoma is a rather rare cancer in Japan, but
the difficulty in diagnosis at an early clinical stage results in its
being one of the most deadly cancers in Japanese women. Some
genetic alterations, such as activation of proto-oncogenes, loss of
tumour-suppressor function and autocrine growth stimulation by
peptide growth factors, may be implicated in the development of
ovarian epithelial cancer, although detailed molecular mechanisms
of ovarian carcinogenesis have never been elucidated (Bast et al,
1993). Abnormal expression of proto-oncogenes, such as HER-
2/neu, c-fins, c-fos, c-myc, n-myc and c-H-ras, has been reported in
ovarian epithelial carcinoma (Tyson et al, 1991; Bast et al, 1993).
C-fins is one of the oncogenes of which abnormal expression is
frequently found in ovarian epithelial carcinoma. It encodes a
transmembrane tyrosine kinase receptor for the macrophage
colony-stimulating factor (M-CSF). As a receptor ofM-CSF, this
is an essential gene for the development ofmacrophages and other
tissues, such as placenta. Recently, attention has been focused on
the association of the gene with the carcinogenesis of non-
haematopoietic tissues. To date, a predominant number of breast,
ovarian and endometrial carcinomas are known to express the c-
fins gene (Kacinski et al, 1990; Kacinski et al, 1991; Bauknecht et
al, 1994). The expression level of c-fins transcripts in ovarian
epithelial carcinoma has been described as correlating strongly
with high-grade histology, advanced clinical presentations and
poor outcome ofthe patients (Kacinski, 1995).
M-CSF is not only a stimulator of macrophage differentiation
but also a stimulator of osteoclast progenitor cell differentiation
(Pollard et al, 1991) and placental development (Pollard et al,
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1987). It is produced by fibroblasts and endothelial cells. In addi-
tion, some kinds of carcinoma, such as ovarian epithelial carci-
nomas, endometrial carcinomas and mammary carcinomas, have
been shown to produce M-CSF (Baiocchi et al, 1991). An abnor-
mally high level of M-CSF is found in the sera of ovarian epithe-
lial carcinoma patients with active disease, and the usefulness of
M-CSF as a tumour marker in ovarian epithelial carcinoma has
been proposed (Kacinski et al, 1989; Suzuki et al, 1993).
It has been shown that recombinant human M-CSF exposure
can lead to the phosphorylation on tyrosine ofa variety ofproteins
in c-fins-positive and M-CSF-negative carcinoma cell lines
(Kacinski et al, 1991), and that M-CSF can accelerate the prolifer-
ation ofc-fins-positive carcinomacells (Croxtall et al, 1992). More
recently, it has been demonstrated that M-CSF treatment could
enhance the invasiveness of cancer cells that express c-fins
(Filderman et al, 1992). These results imply that M-CSF can lead
c-fins-positive cancer cells to a more malignant phenotype. The
fact that a predominant number of ovarian epithelial carcinoma
tissues co-express M-CSF and its receptor (Baiocchi et al, 1991;
Kommoss et al, 1994) suggests that autocrine/paracrine regulation
of M-CSF exists in ovarian epithelial carcinoma cells and leads
them to a more malignant phenotype.
One means of blocking the autocrine loop is to use a hammer-
head ribozyme, which intercepts the mRNA of c-fins. The
hammerhead ribozymes contain two functional modules, i.e. a
catalytic core that cleaves the target RNA and the flanking regions
that, by virtue of complementarity, direct the ribozyme core to a
specific site. By exploiting the flexibility of these two modular
functions, it is possible to design a ribozyme to cleave specifically
any target RNA molecules (Cech and Bass, 1986; Rossi et al,
1991; Dorai et al, 1994). We have studied the possibility of
hammerhead ribozymes as a therapeutic tool against ovarian
epithelial carcinoma cells.
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Figure 1 The corresponding sites of primers and target sites of ribozymes vs the structures of mRNA and gene of c-fms. Although the full length of c-fms
mRNA comes from 22 exons, the partial element of c-fms mRNA is presented. El, exon 1; E2, exon 2; E3, exon 3; CAP, cap of the mRNA
MATERIALS AND METHODS
Cell lines and tissue sample preparation of ovarian
epithelial carcinoma
Ovarian epithelial carcinoma cell lines, TYK-nu, KF, SK-OV3,
Caov3, 2780, and a choriocarcinoma cell line, BeWo, were used in
this study. TYK-nu and KF were kindly provided by the Japanese
Cancer Research Resources Bank (Tokyo, Japan) and Dr Kikuchi
(Kikuchi et al, 1984) respectively. SK-OV3 and Caov3 were
purchased from the American Tissue Culture Collection. All cell
lines were maintained in Eagle minimum essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS) under
an atmosphere of95% air/5% carbon dioxide at 37°C.
Ovarian epithelial carcinoma tissues from nine patients and
placenta were collected immediately after a surgical resection,
minced into small pieces, snap frozen in liquid nitrogen and stored
at -80°C until the study.
Western blotting of c-fms protein
Cultured cells were lysed in the cell lysis buffer (10 mm Tris-HCl,
pH 7.4, 150 mm sodium chloride, 0.1% Triton X-100, 10 mm 2-
mercaptoethanol, 2 jig ml-1 aprotinin and 5 jig ml-1 leupeptin at
40C for 30 min. The cell lysate was centrifuged at 10000 g for 30
min and the supernatant was recovered. Boiled lysates were
subjected to 6% sodium dodecyl sulphate (SDS)-polyacrylamide
gel electrophoresis under reducing conditions and blotted onto
nitrocellulose. The blot was then probed with polyclonal rabbit
anti-c-fins antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Immune complexes were identified and visualized
with an ECL Western blotting kit (Amersham International,
Buckinghamshire, UK).
RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR) for c-fms and M-CSF
Total RNA was extracted using Isogene (NipponGene, Toyama,
Japan). Ovarian carcinoma cell lines were plated on a 10 cm
culture plate. At 48 h after seeding, the total RNA was extracted.
Tissue samples (approximately 100 mg) were suspended in 1 ml of
Isogene and then homogenized. All procedures for extraction were
according to the manufacturer's protocol.
The upstream primer (5'-AACAAGACAAACAGCCAG) was
designed in the 5'-untranslated sequence of c-fins mRNA, and the
downstream primer (5'-AGGGGGTCTCCAGGCTCAGT) was
designed in the sequence of the open reading frame. The corre-
sponding sites ofthe primers, target sites ofthe ribozymes in c-fins
mRNA and the structure of the c-fins gene are shown in Figure 1.
The length of the PCR product was 406 bases. The primers for
M-CSF and G3PDH were derived from the work of other investi-
gators (Kawasaki et al, 1985; Adcock et al, 1994) (M-CSF:
upstream primer, 5'-ACGACATGGCTGGGCTCCCT and down-
stream primer, 5'-TTCTCCAGCAACTGGAGAGGTG. G3PDH:
upstream primer, 5'-TGAAGGTCGGAGTCAACGGAThTTGGT
and downstream primer, 5'-CATGTGGGCCATGAGGTCCAC-
CAC). The PCR product of M-CSF or G3PDH was 407 or 572
bases long respectively. Complementary DNA was synthesized
using Moloney murine leukaemia virus reverse transcriptase
(Takara Shuzo, Kyoto, Japan) with a random hexamer. A 5-gl
aliquot ofcDNA product was submitted to PCR reaction.
PCR was carried out under the following conditions: 35 cycles
of 94°C for 1 min, 55°C for 1 min and 72°C for 1.5 min. PCR
products were electrophoresed in 1.5% agarose gel and analysed
by sequence reaction.
Cloning of PCR products and sequencing
The RT-PCR product ofc-fins from placental RNA was extracted
from the agarose gel and purified using a Gene Clean II kit (Bio
101, LaJolla, CA, USA). The DNA fragment was ligated directly
to PCR TI-vector (Invitrogen, San Diego, CA, USA). After trans-
formation ofE. coli, colonies were selected and screened. Plasmid
DNA was prepared using a Megaprep kit (Qiagen, Chatsworth,
CA, USA).
A double-strand sequence was performed using a CircumVent
thermal cycle dideoxy DNA sequencing kit (New England
Biolabs, Beverly, MA, USA) and 35S-dATP (Du Pont, Wilmington,
DE, USA). At least ten colonies were screened.
In vitro transcription of RNA from plasmid template or
synthetic DNA template
Transcription of RNA from plasmid templates that contained SP6
RNA polymerase promoter was carried out using MAXscript In
Vitro transcription kits (Ambion, Austin, TX, USA). The pCRII
containing the c-fins PCR product was digested with XhoI. The
transcription reaction mixture contained 1 jig oflinearized plasmid
DNA, 0.5 U ml-' SP6 RNA polymerase, 40 mM Tris-HCI, pH 7.5,
6 mm magnesium chloride, 10 mm sodium chloride, 2 mM spermi-
dine, 10 mM dithiothreitol, 0.5 mM ATP, GTP and UTP, 0.1 mM
CTP, 50 jCi of [a-32P]CTP (specific activity 800 Ci mmol-1) (Du
Pont) and 1 U ml-1 recombinant ribonuclease inhibitor in 100g1 of
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In vitro cleavage reaction
The ribozyme and substrate RNA were mixed in a I10-gl reaction
volume containing 50 mm Tris-HCl, pH 7.5, and 1 mM EDTA. The
mixture was heated at 95°C for 2 min, quick cooled on ice, magne-
130 kDa sium chloride was added to a final concentration of 10 mM and then
it was incubated at 370C for various times. The reactions were
stopped by the addition of an equal volume of stop solution (95%
407 bp formamide, 25 mM EDTA, 0.05% bromophenol blue and 0.05%
xylene cyanol) and heated at 650C for 5 min. The reaction mixture
was electrophoresed in a 6% polyacrylamide-7 M urea gel in Tris-
borate EDTA buffer. The reaction was analysed by autoradiography.
4- 572 bp
Figure 2 Western blot analysis of c-fms and RT-PCR analysis of M-CSF
expression in ovarian epithelial carcinoma cell lines. Western blotting of c-
fms protein (top). RT-PCR of M-CSF transcript (middle). RT-PCR of G3PDH
(bottom). Bands of c-fms protein are seen in all seven cell lines at 130 kDa
(immature form) and 160 kDa size (mature form), whereas RT-PCR products
of 407 bases are observed in TYK-nu, 2780, SK-OV3 and Caov-3 cells. PCR
products were analysed by the sequencing reaction
1 2 3 4 5 6 7 8 9 10
C-fms
G3PDH
Figure 3 RT-PCR of c-fms mRNA. A 406-bp fragment of the c-fms gene is
amplified in seven of nine ovarian neoplasms. The PCR products were
analysed by sequencing reaction. Lanes 1-9, cases with serous papillary
adenocarcinoma of the ovary; lane 10, placenta
volume. The reaction was carried out at 370C for 1 h. The reaction
mixture was treated with RNAase-free DNAase followed by
phenol-chloroform extraction and ammonium acetate ethanol
precipitation.
To synthesize the c-fins ribozymes against the GUC of codon
18 and codon 27, two sets of primers were used. To synthesize
the template of the ribozyme against codon 18 (18 ribozyme),
one primer containing the bacteriophage T`7 RNA polymerase
promoter sequence (5'-GGATCCTAATACGACTCACTATAG-
GGATTCCCTCTGATGAG) and the other one (5'-TTGGCATGGT-
TTCGTCCTCACGGACTCATCAGAGGGAAT) were designed.
To synthesize the template of the ribozyme against codon 27
(27 ribozyme), one primer was designed 5'-GGATCCTAATAC-
GACTCACTATAGGCCAGCTCGGGCTGATG and the other was
designed 5'-AGCCCAGTGTTTCGTCCTCTCGGACTCATCAG-
CCCGAGC. The primers were mixed to form ahemiduplex, and the
PCR amplification was performed. The transcription of RNA from
the synthetic DNA template was carried out under similar conditions
except that we used the same amount of cold rNTPs without
[a-32P]CTP. The synthetic DNA template concentration in the
reaction mixture was 0.02 mg ml-'.
Construction of eukaryotic expression vector of
ribozyme and transfection
The 18 ribozyme used for transfection study was designed differ-
ently from that used in the cell-free system. Two single-stranded
oligodeoxynucleotides were synthesized such that the 45-bp
ribozyme contained flanking Sall and XhoI restriction sites on
both ends (5'-pTCGACGGATTCCCTCTGATGAGTCCGTGAG-
GACGAAACCATGCCA and 5'-pAGCTTGGCATGG'TTC-
GTCCTCACGGACTCATCAGAGGGAATCCG). They were 5'
phosphorylated by T4 polynucleotide kinase (New England
Biolabs), annealed and cloned into the pH,APr-l-neo (Gunning et
al, 1987). Of this mammalian expression vector, the transcription
of a cloned gene is driven by the human ,-actin promoter and
augmented by the enhancer element existing in the first inter-
vening sequence ofthe P-actin gene. The sequences following the
initiation codon oftranslation ofhuman 3-actin are replaced by the
polylinker sequence for HindIII, Sall and BamHl restriction
enzymes. The sequence and orientation of the ribozyme in the
vector were confirmed by DNA sequencing with a sequence
primer (5'-GACCAGTGThTTGCCTlTTA-3'). It was designed
from the sequences in the 5'-untranslated region of ,-actin. The
constructed vector was designated pH,BAPr- -neo-18RZ.
Lipofection of TYK-nu cells with pH3APr-l-neo-18RZ or
pH,APr-l-neo was done according to the protocol that the
manufacturer (Gibco-BRL) recommended. In brief, approximately
5 x 104 cells were transfected with 10 gg of the vector DNA that
had been complexed with 50 gl of lipofectin (Gibco-BRL). Three
days after the transfection, G418 was added to the medium to a
flnal concentration of 1 mg ml. The transfected cells had been
exposed to G418 for 4 weeks. In total, 12 clones or 26 clones were
obtained from transfectants with pHPAPr-l-neo-18RZ or
pHbAPr- -neo respectively. The pooled clones of each transfec-
tant were named TYK-nu-I8RZ and TYK-nu-pHAP.
RT-PCR and Southern blot analysis for ribozyme
expression
Total RNA was extracted from the transfectants and parental
TYK-nu cells using Isogene (Nippongene). Total RNA (500 ng)
from each transfectant was reverse-transcribed with a random
hexamer, followed by PCR using two primers: 5'-AGCACA-
GAGCCTCGCCTTT (from ,B-actin 5'-untranslated region) and 5'-
TGGATCCCTCGAAGCFT (from plasmid polylinker). The
cycling conditions were as follows: 94°C for 30 s, 47°C for
3 min and 72°C for 2 min for 25 cycles. PCR products were
electrophoresed in 1.5% agarose gel and mounted on a nylon
membrane by capillary transfer. The membrane containing an
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Figure 4 Hammerhead ribozymes are designed to target the GUC sequence of the codon 18 and the codon 27 of c-fms mRNA
amplified 119-bp DNA was hybridized using a 32P-labelled probe,
complementary to the conserved catalytic sequences of the
ribozyme (5'-CCTCACGGACTCATCAG). The labelling of the
oligomer was carried out by T4 polynucleotide kinase (Toyobo,
Tokyo, Japan) and [y-32P]ATP (Du Pont).
Northern blotting and Western blotting for c-fms of
transfectants
Total RNA was extracted as described before. Total RNA (10 ,ug)
was loaded on 0.8% agarose/formaldehyde gel and elec-
trophoresed, and then the RNA was mounted on a nylon
membrane by capillary transfer. Northern blotting was carried out
using c-fins cDNA cloned into the pCRII vector and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) cDNA (Clontech
Laboratories, Palo Alto, CA, USA).
Cells in log-phase growth were lysed in the cell lysis buffer as
described before. Protein (20 jig) was loaded onto 8% poly-
acryamide gel, electrophoresed and analysed by Western blotting
as described before.
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Cell proliferation assay
Approximately 5 x 104cells were suspended in 20 ml ofDulbecco's
MEM without FBS and seeded onto a 10-cm culture dish. After
24 h, the number of cells in a dish was counted as a control. On
the basis ofthis number, cell proliferation was evaluated.
The number ofcells in the dish was counted at 1, 3 and 5 days,
and the growth rate was expressed as a number relative to the
control. The experiment was carried out in triplicate. Results
obtained were evaluated by Student's t-test.
RESULTS
First, we sought to determine whether the c-fms protein and the M-
CSF transcript are in fact expressed in ovarian carcinoma cell lines
and carcinoma tissues. As a positive control, we used human
placental tissue and BeWo cells. Figure 2 shows that, at steady
state, all five cell lines expressed c-fms proteins and that TYK-flu,
2780, SK-OV3 and Caov-3 cells expressed the M-CSF transcript,
indicating that an autocrine loop ofM-CSF may exist in these four
cell lines. In tissue samples ofovarian epithelial carcinoma, c-fins
Short exposure
of 2581267 bp ...........
Figure 5 In vitro cleavage reaction by the 18 ribozyme and the 27
ribozyme. Under the conditions of a molar ratio of ribozyme to RNA substrate
of 5:1, 10 mm magnesium chloride in 50 mm Tris HCI, pH 7.4 both the 18
ribozyme and the 27 nbozyme cleaved the c-fms RNA substrate in a time-
dependent manner. Bottom left: a short exposure autoradiogram of cleaved
fragments by the 18 ribozyme. Two bands of 267 and 258 bases are clearly
observed
expression was found in seven of nine cases by the RT-PCR
technique (Figure 3).
Because ribozymes recognize a GUC sequence and cleave it
most efficiently, attempts were made to determine whether a GUC
sequence is located within any critical region on c-fins mRNA.
There are 32 GUC sequences in the coding regions, three GUC
sequences in the 5'-untranslated regions and ten GUC sequences in
the 3'-untranslated regions. Because cleavage within the open
reading frame of c-fins mRNA by ribozymes will be able to
destroy the function ofmRNA completely, and the distal region of
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Figure 6 Expressions of c-fmstranscript, protein and ribozyme in parental
TYK-nu cells and transfectants. Western blot analysis of c-fms protein
expression (top), Northern blot analysis of c-fms mRNA expression (second
from top). Northern blot analysis of G3PDH mRNA expression (second from
bottom). RT-PCR and Southem blot analysis of ribozyme expression
(bottom). Note that the transfectant with pHbAPr-1-neo-18RZ shows
diminished expression of c-fms protein and mRNA with the expression of the
ribozyme
the open reading frame is likely to be exposed at the outer surface
of the three-dimensional structure of the mRNA, we chose the
GUC sequences of codons 18 and 27 as target sites ofribozymes.
Two kinds of hammerhead ribozymes were designed to target the
GUC sequence in these codons of c-fins mRNA, based on the
model proposed by Haseloffand Gerlach (1988). The sequences of
the target site and the hammerhead ribozymes are shown in Figure
4. Oligonucleotides encoding the catalytic core of the ribozyme,
the flanking sequences complementary to the target sequence and
a T7 RNA polymerase promoter were synthesized. After anealing
a pair of deoxyoligonucleotides containing the T7 promoter
sequence and the ribozyme sequence, a double-stranded synthetic
substrate was made by a PCR method. It was transcribed with T7
RNA polymerase to generate 44-base ribozymes, according to
published procedures (Milligan et al, 1987).
To create a synthetic c-fins substrate RNA, a fairly large region
encompassing the target site, which could thus mimic the
secondary structures in the native mRNA, was selected between
the 5'-untranslated region and the codon 91 of c-fins mRNA.
Sequence analysis of the cloned PCR product indicated that there
were no mutations in the c-fins mRNA in the region amplified,
which included the target sites. Transcribing the sense RNA
construct by SP6 RNA polymerase yielded a 525-base labelled
RNA substrate. This substrate and the ribozymes were mixed at a
molar ratio of 1:5, and a cleavage reaction was then observed in
the cell-free system. As shown in Figure 5, the hammerhead
ribozymes against codon 18 and 27 cleaved the 525-base c-fins
substrate into 267- and 258-base fragments and 296- and 219-base
fragments respectively. The cleaved fragments were the correct
sizes, as predicted from the location of the cleavage site of the
Figure 7 Growth curves of parental TYK-nucells and transfectants. Cells
from transfectants and parental cells were seeded in serum-free Dulbecco's
MEM and were grown on Falcon tissue culture dishes as described in
Materials and methods. Cells were counted at 24 h after seeding as a
control. Cell growth was evaluated from the first day to the fifth day. Each
point represents the mean of triplicate determinations (0, parental TYK-nu
cells; 0, TYK-nu-pHAP; 0, TYK-nu-18RZ; *P< 0.05)
ribozyme. The cleavage occurred in a time-dependent manner.
The 18 ribozyme more efficiently cleaved the substrate than the
27 ribozyme.
By the introduction ofpHPAPr-1-neo or pH,APr-1-neo-18RZ
into TYN-nu cells and selection with 1 mg ml' G418, we obtained
26 colonies oftransfectant withpHPAPr-1-neo and 12 colonies of
transfectant with pH3APr-l-neo-18RZ. In each case, we collected
the colonies as a pooled clone. First, we studied the expression of
the ribozyme by RT-PCR and Southern blot analysis. As shown in
Figure 6, ribozyme expression was found only in the transfectant
with pH3APr-l-neo-18RZ, implying that the ribozyme RNA was
successfully expressed in this pooled clone.
The expression of c-fins in the transfectants was analysed by
Western blotting as well as by Northern blotting. The expression
level of the c-fins transcript in the transfectant with pH,APr-1-
neo-18RZ was clearly reduced with a decrease in c-fms protein
expression compared with that of parental TYK-nu cells or the
transfectant withpHPAPr-I-neo (Figure 6).
Next, we studied the growth potential of the transfectants. The
proliferation rates of transfectants and parental TYK-nu cells are
shown in Figure 7. In order to ignore the influence of exogenous
M-CSF, the growth potential was evaluated under serum-free
conditions. The transfectant with pH,BAPr-l-neo-18RZ grew more
slowly than parental TYK-nu cells and TYK-nu-PH cells. The
difference in the growth rate was statistically significant atthe fifth
day [P < 0.05, 4.2 ± 0.4 (s.d.) of TYK-nu-18RZ vs 5.2 ± 0.4 of
parental TYK-nu cells].
DISCUSSION
To date, c-fins is among the most significant oncogenes involved in
ovarian carcinogenesis (Gallion and Bast, 1993). Abnormal expres-
sion of H-ras, K-ras, C-myc or N-myc was found in some ovarian
epithelial carcinomas, but the frequency ofthese abnormalities was
much less than that of c-fins (Roussel, 1994). C-erbB-2 is a coun-
terpart, of which abnormal expression is often found in ovarian
carcinoma. The frequency ofthe expression or the gene amplifica-
tion has been reported in 86% or 30% of ovarian epithelial carci-
nomas respectively (Tyson et al, 1991). However, the evidence of
autocrine and/or paracrine regulations through c-erbB-2 has never
been demonstrated in ovarian epithelial carcinoma.
British Journal ofCancer(1997) 76(8), 977-982 0CancerResearch Campaign 1997982 Y Yokoyama etal
In the present study, we found that the c-fins as well as the M-
CSF transcript and/or protein was expressed in a predominant
number ofovarian epithelial carcinoma tissues and cell lines. Our
observation was largely based on the RT-PCR technique, and posi-
tive RT-PCR does not mean substantial existence of proteins.
Frequent co-expression ofthese transcripts in ovarian carcinomas,
however, has been reported by other investigators (Baiocchi et al,
1991; Bauknecht et al, 1994). Taken together, it is conceivable that
autocrine regulation of M-CSF may exist in some ovarian epithe-
lial carcinomas. In addition, M-CSF can be secreted by the
surrounding stromal cells and endothelial cells. It can affect
ovarian carcinoma cells that express the c-fms protein by a
paracrine mechanism. Female reproductive tissues are the major
sites at which M-CSF is produced. During pregnancy, synthesis of
M-CSF markedly increases at the epithelium of the oviducts and
the endometrium of the uterus (Arceci et al, 1989). Normal
ovarian epithelium expresses M-CSF (Lidor et al, 1990). In such
an environment, acquisition ofc-fins expression ofovarian epithe-
lial cells can establish autocrine/paracrine stimulation by M-CSF
and may consequently lead the cells to malignant transformation.
Because the target site of ribozymes must be sufficiently
exposed on the outer surface of the three-dimensional structure of
the mRNA forthe ribozyme to access (Tiara and Nishizawa, 1992),
we first studied which target site is more effective for ribozyme
cleavage, the GUC sequence ofcodon 18 or that ofcodon 27 c-fins
inRNA. An in vitro cleavage study showed that the ribozyme
against codon 18 was much more efficient than that against codon
27. Therefore, we chose the 18 ribozyme for the transfection study.
We could successfully reduce the expression level of the c-fms
protein in TYK-nu cells by the introduction of the 18 ribozyme.
Reduced expression of the c-fms protein resulted in the decreased
growth potential of the cells. This result strongly implicates the
pathological role of this oncogene in the development of ovarian
cancer. Wehave shownthat theGUC sequence ofcodon 18 is agood
target site of the ribozyme, but the 18 ribozyme could not totally
extinguish the expression ofc-fms. This may be attributed to further
difficulty of the ribozyme in accessing the target site. To search for
better target sites, a further study is in progress at our laboratory.
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